Drug Interaction API Pricing: $0 vs $99 vs $10K+ (2026)

If you have ever tried to find pricing for a drug interaction API, you know the experience: you search for a product, find a marketing page describing enterprise-grade clinical decision support, and are directed to contact sales or request a quote. No pricing page. No self-service sign-up. No way to evaluate cost without a phone call and a procurement timeline.

This opacity is the norm in health IT, not the exception. DrugBank, First Databank (FDB), Micromedex, Elsevier's Clinical Pharmacology, and Wolters Kluwer's Lexicomp all follow variations of this pattern. There are historical reasons for it: these products often bundle drug interaction data with broader clinical decision support suites, and pricing depends on factors like number of users, deployment model, and contract term. Enterprise software has always operated this way.

But the market is changing. Developers building healthcare applications are accustomed to transparent, usage-based pricing from infrastructure providers like AWS, Stripe, and Twilio. They want to evaluate cost before engaging with a sales team. They need to estimate unit economics for their own products before committing to a data vendor. And they increasingly expect a free tier to validate that a product meets their technical requirements before spending anything at all.

This article provides the most comprehensive publicly available comparison of drug interaction API pricing as of March 2026. Where vendors publish pricing, we cite it directly. Where they do not, we report what is publicly known and indicate where a sales conversation is required. We also break down the hidden costs that are easy to overlook: integration engineering time, ongoing maintenance, data currency guarantees, and support responsiveness.

RxLabelGuard publishes its complete pricing at /pricing with no hidden tiers or sales-gated plans. There are three tiers, all self-service.

The Sandbox tier is free, permanently. It provides 50 API requests per month, 1 API key, structured response format only, and community support. No credit card is required to sign up. This tier is designed for evaluation, prototyping, and personal projects. You can sign up at /register and start making API calls in minutes.

The Developer tier is $20 per month. It includes 2,000 requests per month, up to 5 API keys, all three response formats (structured, summary, and conversational), and email support. Overage pricing is $0.015 per request above the included allocation. At this tier, the effective cost per request ranges from $0.01 (using the full allocation) to $0.015 (all overage). The Developer tier is designed for teams building and launching integrations, running staging environments, and serving moderate production traffic.

The Professional tier is $99 per month. It includes 20,000 requests per month, unlimited API keys, all response formats, priority support with a 24-hour SLA, and a 99.5% uptime SLA. Overage pricing is $0.008 per request. At full utilization, the effective cost per request is $0.00495. The Professional tier is designed for production workloads serving healthcare applications, pharmacy systems, and clinical decision support platforms.

For teams needing more than 20,000 requests per month, enterprise pricing is available by contacting support@rxlabelguard.com. The key distinction from other vendors: even the enterprise conversation starts from a published baseline, not a blank quote.

DrugBank offers one of the most comprehensive curated drug databases in the industry, with detailed pharmacological data, interaction records, and structured drug information. Their API provides programmatic access to this data, including a dedicated Drug-Drug Interaction (DDI) Checker API.

DrugBank's pricing is not publicly listed. The commercial API requires a licensing agreement, and pricing is provided through their sales team. Based on publicly available information, DrugBank offers academic licensing (which is free or reduced-cost for qualifying academic institutions), commercial licensing (which varies by use case, deployment model, and scale), and the DDI Checker API as either a standalone product or part of a broader DrugBank API license.

What is publicly known: DrugBank's free web-based Drug Interaction Checker at go.drugbank.com is retiring on March 25, 2026. This tool allowed checking up to five drugs at a time with limited result depth. Its retirement does not affect the commercial API or the embeddable clinical plugin, which remain available as paid products. For teams that depended on the free checker, the migration path leads to either DrugBank's commercial offerings or alternative solutions. Our analysis at /drugbank-api-alternative covers this transition in detail.

For budgeting purposes, enterprise drug database licensing in healthcare IT typically starts in the low five figures annually and can reach six figures for large deployments with multiple integration points. DrugBank's exact positioning within that range depends on negotiation, but teams should plan for a meaningful annual commitment plus integration engineering time.

First Databank (FDB) is a Hearst Health company and one of the oldest drug information providers in the industry. Their MedKnowledge product suite includes drug interaction screening, dosage checking, allergy screening, and a wide range of clinical decision support capabilities. FDB data is embedded in many major EHR systems, pharmacy dispensing systems, and health plan platforms.

FDB does not publish pricing. Their products are sold through an enterprise sales model, typically as multi-year licensing agreements. FDB MedKnowledge is often bundled with other Hearst Health products, making it difficult to isolate the cost of drug interaction data specifically. FDB also offers FDB Vela, a cloud-based clinical decision support API, which may offer more modular pricing for API-centric use cases.

Based on industry reports and publicly available contract information, FDB licensing is positioned at the mid-to-upper end of the market. Contracts often include minimum commitments, per-seat or per-transaction pricing, and implementation fees. For a small health tech company evaluating FDB, expect the evaluation process itself to take weeks to months, involving sales calls, technical assessments, and legal review of data licensing terms. Our comparison of FDB alternatives at /alternatives/first-databank provides additional context for teams evaluating this path.

FDB's strength is depth and breadth: decades of editorial curation, wide coverage of drug-drug, drug-food, and drug-allergy interactions, and deep integration with clinical workflow systems. For organizations already using FDB data through their EHR vendor, adding interaction checking may be a natural extension. For smaller teams or those building a new product, the procurement overhead can be a significant barrier.

Micromedex, now part of Merative (formerly IBM Watson Health), provides a comprehensive clinical decision support suite that includes drug interaction checking as one component of a larger product. Micromedex drug interactions are backed by an editorial team that evaluates clinical evidence and assigns severity and documentation levels to each interaction pair.

Like FDB, Micromedex does not publish pricing. The product is sold through enterprise agreements, often to hospitals, health systems, and pharmacy benefit managers. Micromedex is frequently bundled with other Merative clinical reference products, including DRUGDEX, POISINDEX, and DISEASEDEX. The interaction checking capability is rarely sold as a standalone API.

For teams evaluating Micromedex specifically for drug interaction API access, the path typically involves engaging with Merative's sales organization, scoping a deployment model, and negotiating a multi-year contract. Implementation timelines can extend to months, depending on the integration complexity and the organization's procurement processes. Our comparison at /alternatives/micromedex discusses the technical and operational considerations for teams evaluating this option.

Micromedex's editorial quality is widely respected in clinical settings, and its severity scoring methodology is well-documented. However, for development teams that need API access to drug interaction data specifically, the bundled enterprise model introduces cost and complexity that may not align with their needs, particularly for startups and smaller health tech companies.

The openFDA drug label API is free to use. There is no licensing cost, no contract, and no sales conversation required. The API provides access to FDA Structured Product Labeling data, including the drug_interactions section of each label. With a free API key from open.fda.gov, you get 240 requests per minute and 120,000 requests per day.

The catch is that openFDA provides raw label text, not structured interaction data. The drug_interactions field contains prose written by pharmaceutical manufacturers: paragraphs describing interaction mechanisms, recommendations, and affected drug classes. Turning this text into structured, severity-scored interaction pairs requires building an extraction pipeline that includes drug name normalization (via RxNorm), label retrieval and caching, natural language processing or LLM-based extraction, severity classification, cross-matching between drug pairs, and response formatting with evidence citations.

The engineering cost of building this pipeline is the true price of the openFDA option. Based on our own experience building this exact pipeline for RxLabelGuard, a conservative estimate for a small team is 3 to 6 months of focused engineering effort for the initial build, followed by ongoing maintenance for extraction accuracy, cache management, and API changes. At a blended engineering cost of $150 per hour, that initial build represents $72,000 to $144,000 in engineering time, plus $2,000 to $5,000 per month in ongoing maintenance and infrastructure costs.

For teams with the engineering capacity and a strategic reason to own the pipeline (regulatory requirements, custom extraction logic, or deep integration with proprietary clinical workflows), building on openFDA can make sense. Our developer guide to the openFDA drug label API at /blog/openfda-drug-label-api-developer-guide covers the technical details for teams considering this approach. For teams that need interaction data as a building block within a larger product, buying API access is almost always more economical than building.

To make this comparison practical, here is how costs break down across four common scenarios. These estimates use published pricing where available and conservative estimates where pricing is not public. Engineering time is valued at $150 per hour.

Scenario 1: Solo developer building a side project. The need is basic interaction checking for a prototype or personal project, with under 100 requests per month. RxLabelGuard Sandbox is $0 per month with 50 requests included. openFDA DIY is $0 in API costs but requires weeks of engineering time to produce structured output. DrugBank, FDB, and Micromedex are not realistically accessible for this scenario due to enterprise sales requirements.

Scenario 2: Startup building an MVP. The need is 500 to 2,000 requests per month for a healthcare application in development or early production. RxLabelGuard Developer is $20 per month. openFDA DIY is $0 in API costs plus approximately $72,000 or more in initial engineering plus ongoing maintenance. DrugBank commercial API is available through sales engagement, likely in the range of $10,000 to $50,000 annually depending on use case and negotiation.

Scenario 3: Small health tech company in production. The need is 5,000 to 20,000 requests per month serving a clinical application. RxLabelGuard Professional is $99 per month. openFDA DIY costs approximately $2,000 to $5,000 per month in infrastructure and engineering maintenance (after the initial build). DrugBank and FDB commercial licenses are typically in the $25,000 to $100,000 per year range for this scale.

Scenario 4: Enterprise health system or large pharmacy chain. The need is over 100,000 requests per month with SLA requirements, support contracts, and compliance needs. RxLabelGuard Enterprise is available by contact. DrugBank, FDB, and Micromedex enterprise agreements typically range from $50,000 to $250,000 or more annually, often bundled with broader clinical decision support capabilities. At this scale, the choice often depends on factors beyond pure interaction data: editorial methodology, regulatory posture, existing vendor relationships, and clinical workflow integration depth.

Published pricing tells only part of the story. Several hidden costs can significantly affect the total cost of ownership for a drug interaction data source.

Integration engineering time is the largest hidden cost. Even with a well-documented API, integrating drug interaction checking into a clinical workflow requires development effort: building the request/response layer, mapping drug identifiers between your system and the API, implementing error handling and retry logic, designing the user interface for displaying interactions to clinicians or patients, and building audit logging for compliance. For enterprise databases like FDB and Micromedex, integration complexity is typically higher due to more complex data models and custom deployment requirements. Budget 40 to 200 hours of engineering time for a typical integration, depending on the product and your application's complexity.

Data currency and update frequency matter for clinical applications. FDA labels update irregularly. Curated databases like DrugBank and FDB update on their own editorial schedules. Understanding how current the interaction data is, and how quickly new interactions are reflected after FDA label updates, is important for clinical safety. Some vendors provide update guarantees in their SLAs; others do not. Ask about this during evaluation.

Support responsiveness can be a hidden cost when things go wrong. A production incident involving a missed or incorrect interaction requires fast resolution. Free tiers and low-cost plans typically offer community support or email support without SLA guarantees. Enterprise contracts usually include defined response times, but the quality and availability of support varies significantly between vendors.

Vendor lock-in is a long-term cost that is easy to underestimate. Migrating between drug interaction data sources is not trivial, because each vendor uses different identifiers, severity scales, and data structures. Building an abstraction layer over your chosen data source is wise, but adds its own development cost. Consider how dependent your application's core logic will be on the specific format and conventions of your chosen vendor.

Choosing the right pricing tier depends on four factors: your current request volume, your growth trajectory, your need for response format flexibility, and your support requirements.

If you are exploring or prototyping, start with the free Sandbox tier at /register. Fifty requests per month is enough to validate the API against your drug list, test your integration code, and evaluate response quality. There is no time limit on the free tier and no credit card required. You can remain on the free tier indefinitely if your needs are met.

If you are building a product and need more than 50 requests per month, or if you need summary or conversational response formats, the Developer tier at $20 per month is the natural upgrade. Five API keys let you separate production, staging, and development environments. The $0.015 per request overage pricing means you can handle traffic spikes without pre-purchasing a higher tier.

If you are running a production healthcare application serving clinicians or patients, the Professional tier at $99 per month provides the volume, reliability, and support guarantees that production workloads require. The 99.5% uptime SLA, 24-hour priority support response time, and $0.008 per request overage pricing are designed for applications where reliability and cost predictability matter. Unlimited API keys allow per-application or per-environment key management without artificial limits.

If your needs exceed the Professional tier, reach out for enterprise pricing. We work with teams to build custom arrangements that address high-volume requirements, dedicated support channels, and compliance documentation needs.

The fastest way to evaluate a drug interaction API is to use it. Create a free account at /register, generate an API key from your dashboard, and make your first API call. The entire process takes under five minutes.

If you are comparing multiple vendors, we recommend running the same set of drug pairs through each option you are evaluating. Submit a mix of well-known interactions (warfarin plus aspirin), less obvious interactions (metformin plus contrast dye), and drugs with no known interactions (acetaminophen plus levothyroxine). Compare the results for completeness, severity accuracy, response structure, and evidence quality. Our comparison page at /compare provides a structured framework for this evaluation.

For teams migrating from the retiring DrugBank free checker, our migration guide at /blog/drugbank-interaction-checker-retiring-alternatives-2026 covers the timeline, alternatives, and technical considerations. For teams that previously used the NLM Drug Interaction API, our guide at /blog/nlm-rxnav-drug-interaction-api-discontinued-migration-guide covers that migration path.

Transparent pricing should be the baseline, not the exception, for developer tools in healthcare. We publish our pricing because we believe developers deserve to evaluate cost alongside technical fit, without a sales gate. The pricing page at /pricing has the full details.